Enliven Therapeutics, Inc. Profile Avatar - Palmy Investing

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being …

Biotechnology
US, Boulder [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of ELVN's Analysis
CIK: 1672619 CUSIP: 29337E102 ISIN: US29337E1029 LEI: - UEI: -
Secondary Listings
ELVN has no secondary listings inside our databases.